Equity Briefing : Pluristem's PLX cells may change bone marrow transplantation as well as other potential indications
(Thomson Reuters ONE) -
CEO of Pluristem Therapeutics, Inc. (NASDAQCM:PSTI( (TASE: PLTR) tells
shareholders that his firm's PLX cells may be effective in supporting bone
marrow transplantation as well as other potential indications where bone marrow
may be suppressed, such as radiation and chemotherapy.
Additionally, work done in animals using PLX cells in Acute Radiation Sickness
(ARS) provides another data point to approach that PLX cells can be
administered locally into skeletal muscle, distant to the target organ, and
obtain efficacious systemic effects.
Pluristem received U.S. Food and Drug Administration (FDA) clearance to begin a
Phase II clinical trial using PLX-PAD intramuscularly for the treatment of
Intermittent Claudication (IC), a subset of peripheral artery disease (PAD). The
trial will evaluate the safety and efficacy of two doses (150x10(6) cells and
300x10(6) cells) of PLX-PAD versus placebo administered via one or two
intramuscular (IM) injections. The study population will be comprised of IC
patients, Fontaine class IIb; Rutherford category 2-3 and will be conducted at
several leading U.S. clinical sites.
Recently the compassionate use of Pluristem's PLX Cells saved the life of a
child after a bone marrow transplantation failure failed.
Source: http://yhoo.it/JpzxT0
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Equity Briefing via Thomson Reuters ONE
[HUG#1614288]
Datum: 23.05.2012 - 14:11 Uhr
Sprache: Deutsch
News-ID 149416
Anzahl Zeichen: 1976
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 136 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Equity Briefing : Pluristem's PLX cells may change bone marrow transplantation as well as other potential indications"
steht unter der journalistisch-redaktionellen Verantwortung von
Equity Briefing (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
